GLP1R and Hypoglycemia: Blockade of GLP-1 action through intravenous Ex-9 in individuals with PHH reduced postprandial insulin secretion by around 50–70% [143,144,175], increased the glucagon levels, increased the postprandial glucose levels (including the nadir glucose levels) and reduced the risk and symptoms of hypoglycaemia [143,144] (Table 3).